Lilly Teams Up With Boehringer Ingelheim To Boost Abemaciclib
The two big pharmas are working together in oncology in an effort to advance combination therapies in both their growing, but young oncology pipelines.
You may also be interested in...
The private company has stressed home-grown candidates, but it's making more external plays as it builds oncology as one of the pillars of the business.
Continuation of Phase III MONARCH 2 study, with no early termination for efficacy, may mean a delay in filing and a tougher competitive outlook against Pfizer's Ibrance and Novartis' ribociclib.
Although Jardiance is supported by outcomes data, it has not yet been incorporated into labeling, nor has it translated into greater sales.